Skip to main content
. 2009 Jul 6;3:35–45. doi: 10.4137/bcbcr.s2905

Table 1.

Baseline status.

Group
p values
IMS (n = 30) Control (n = 31)
Age in years (mean, ±SD; t-test) 48.4 ± 7.5 50.8 ± 8.0 0.228
Tumour status (n; Chi square test)
  Tumour classification 0.879
    T1 7 9
    T2 21 19
    T3 1 2
    Tx 1 1
  Pos. lymph nodes 0.343
    N0 10 16
    N1 19 14
    N2 1 1
  Tumour grade 0.963
    G1 1 1
    G2 24 24
    G3 5 6
Menopause status (n; Kruskal-Wallis test) 0.349
  Premenopausal 17 13
  Perimenopausal 2 1
  Postmenopausal 11 17
Receptor status estrogen 0.714
  + 20 17
  − 8 12
  Unknown 2 2
Receptor status progesteron 1.000
  + 18 19
  − 10 10
Unknown 2 2
Body Mass Index (mean, ±SD; t-test) 27.0 ± 6.3 25.6 ± 4.7 0.709
Karnofsky-Index (mean, ±SD) 100 ± 0.0 100 ± 0.0
Abnormal findings on physical examination (n) 0 0
Vital signs (mean, ±SD; t-test)
  Blood pressure systolic mm(Hg) 130.0 ± 20.0 132.2 ± 19.0 0.661
  Blood pressure diastolic mm(Hg) 81.7 ± 12.5 83.6 ± 13.6 0.568
  Pulse (/m) 82.3 ± 13.4 77.1 ± 10.1 0.094
  Temperature (°C) 36.5 ± 0.1 36.6 ± 0.1 0.268
Previous diseases (n) 0 0
Primary endpoints
  Neutropenia (n) 0 0
EORTC-QLQ-C30 (mean, ±SD; Mann-Whitney U-test)
  Global health status 67.8 ± 20.4 68.5 ± 18.3 0.868
  Physical functioning 86.0 ± 14.2 86.0 ± 12.4 0.852
  Role functioning 65.5 ± 20.9 73.0 ± 16.9 0.143
  Emotional functioning 75.8 ± 20.1 74.1 ± 18.1 0.623
  Cognitive functioning 85.0 ± 20.7 79.3 ± 23.4 0.267
  Social functioning 76.7 ± 19.4 80.5 ± 18.9 0.424
  Fatigue 22.6 ± 17.2 25.7 ± 19.5 0.593
  Nausea and vomiting 3.4 ± 9.3 2.9 ± 7.8 0.959
  Pain 21.7 ± 21.5 16.1 ± 20.6 0.210
  Dyspnoea 4.6 ± 14.7 3.4 ± 10.3 0.965
  Insomnia 16.8 ± 21.1 23.0 ± 31.0 0.557
  Appetite loss 12.6 ± 22.6 10.3 ± 20.1 0.625
  Constipation 7.8 ± 14.3 6.9 ± 13.7 0.808
  Diarrhoea 2.2 ± 8.5 2.3 ± 8.6 0.972
  Financial difficulties 23.3 ± 23.4 20.7 ± 30.1 0.358